Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
. Cell Rep. 2021 Sep 7;36(10):109655. doi: 10.1016/j.celrep.2021.109655. Cell Rep. 2021. PMID: 34496253
.
Item in Clipboard